citarinostat

Drug Overview

Citarinostat is a highly specialized medication currently being studied in advanced cancer research. It is designed as a “Targeted Therapy” or “Smart Drug,” meaning it is built to attack specific parts of cancer cells without harming as many healthy cells as traditional treatments do. Citarinostat is taken as a pill, making it a convenient option for patients participating in clinical trials.

While it is not yet available at your local pharmacy, it represents an exciting step forward in personalized cancer care, particularly for hard-to-treat blood cancers and certain solid tumors.

Here are the key details about this medication:

• Generic Name: Citarinostat (often referred to in research as ACY-241).
• US Brand Names: None currently. It is an investigational drug.
• Drug Class: Targeted Therapy / Histone Deacetylase (HDAC) Inhibitor (Specifically, an HDAC6 inhibitor).
• Route of Administration: Oral (taken by mouth as a tablet or capsule).
• FDA Approval Status: Currently investigational. It is not yet FDA-approved for standard public use, but it is actively being studied in clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand how citarinostat works, it helps to look closely at how cancer cells survive. Citarinostat is a “Targeted Therapy” that focuses on blocking a specific enzyme in the body called Histone Deacetylase 6 (HDAC6).

Here is how the drug works at the molecular level:

1. The Cell’s Trash System: Cancer cells, especially in blood cancers like Multiple Myeloma, grow very fast and produce a lot of abnormal proteins. To survive, the cancer cell must constantly clean up these junk proteins. The enzyme HDAC6 acts like the manager of the cell’s waste disposal system (called the aggresome pathway).
2. Blocking the Manager: When a patient takes citarinostat, the drug enters the cancer cells and firmly attaches to the HDAC6 enzyme, blocking it from doing its job.
3. Protein Build-Up: Because the waste system is shut down, toxic, misfolded proteins quickly pile up inside the cancer cell.
4. Cell Death (Apoptosis): The massive build-up of junk proteins causes the cancer cell to experience severe stress. Eventually, this stress triggers a self-destruct signal, causing the cancer cell to die.

Because healthy cells do not produce as many abnormal proteins as cancer cells do, they are much less affected by the drug. This is why citarinostat is considered a “Smart Drug.”

FDA-Approved Clinical Indications

Because citarinostat is an investigational agent, it does not currently have official FDA-approved indications for routine, everyday medical practice. However, it is being actively tested in clinical trials for the following purposes:

Oncological Uses (In Clinical Trials):

• Multiple Myeloma: Used frequently in combination with other cancer-fighting drugs (like pomalidomide) to treat patients whose blood cancer has returned or stopped responding to standard care.
• Solid Tumors: Being tested in patients with advanced solid tumors, such as non-small cell lung cancer (NSCLC) and melanoma, to see if it can stop tumor growth.

Non-oncological Uses:

• Currently, there are no broad non-oncological uses being studied. The main focus of citarinostat is entirely on fighting cancer.

Dosage and Administration Protocols

Because citarinostat is an investigational pill, the exact dose depends heavily on the specific rules of the clinical trial a patient joins.

Clinical Efficacy and Research Results

Recent clinical studies conducted between 2020 and 2025 show promising early results for citarinostat, particularly as a team player. Because cancer cells are smart and can learn to hide from a single drug, researchers often combine citarinostat with other treatments.

• Combating Drug Resistance: Studies show that when citarinostat is added to standard myeloma drugs (like pomalidomide or paclitaxel), it helps overcome the cancer’s resistance. It makes the cancer cells more vulnerable to the primary treatment.
• Patient Outcomes: In Phase 1 and Phase 2 trials for relapsed Multiple Myeloma, patients taking this combination have shown encouraging signs of disease stabilization. While exact long-term survival rates are still being calculated in ongoing studies, a significant number of patients experienced a partial response, meaning their cancer burden was noticeably reduced.
• Solid Tumor Control: In solid tumors, research indicates that citarinostat can help stall disease progression, giving patients more time before the tumor begins to grow again.

Safety Profile and Side Effects

Like all cancer treatments, citarinostat can cause side effects. However, because it targets a specific enzyme, it generally avoids the severe hair loss and extreme sickness caused by traditional chemotherapy.

Black Box Warning: There is no FDA Black Box Warning for this investigational agent at this time.

Common Side Effects (>10%):

• Fatigue: Feeling unusually tired or weak.
• Gastrointestinal Issues: Mild to moderate nausea, diarrhea, or upset stomach.
• Thrombocytopenia: A drop in blood platelets, which can cause easy bruising or bleeding.
• Anemia: A drop in red blood cells, leading to paleness and shortness of breath.

Serious Adverse Events:

• Severe Neutropenia: A significant drop in white blood cells. This is serious because it lowers the immune system and heavily increases the risk of catching a dangerous infection.

Management Strategies:

• If nausea occurs, doctors can prescribe anti-nausea medication to be taken before the citarinostat dose.
• Patients will undergo frequent blood tests. If white blood cell or platelet counts drop too low, the doctor will pause the medication until the blood recovers, and then restart it at a lower dose.

Research Areas

While citarinostat is not directly a stem cell therapy, it is heavily involved in the broader field of advanced “Targeted Therapy” and “Immunotherapy” combinations. Current research is heavily focused on how blocking the HDAC6 enzyme might change the environment around a tumor, potentially making it easier for the patient’s own immune system (or other immunotherapy drugs) to recognize and attack the cancer cells. Researchers are exploring how this smart drug can act as a key to unlock the full potential of the body’s natural defenses.

Patient Management and Practical Recommendations

To ensure safety and the best possible results during a clinical trial, patients taking citarinostat must follow careful guidelines.

Pre-treatment Tests to be Performed:

• Complete Blood Count (CBC): To ensure red cells, white cells, and platelets are at safe levels before starting.
• Comprehensive Metabolic Panel: To check that the liver and kidneys are functioning well enough to process the drug.
• Pregnancy Test: A negative pregnancy test is required for women of childbearing age, as the drug could potentially harm an unborn baby.

Precautions During Treatment:

• Because the drug can lower white blood cells, patients must be highly cautious about infections.
• Watch closely for any signs of unexplained bruising, nosebleeds, or a fever over 100.4°F (38°C), and report these to the medical team immediately.

“Do’s and Don’ts” List:

• DO take the pill at the same time every day to keep a steady amount of medicine in your body.
• DO swallow the pills whole with a full glass of water.
• DO wash your hands frequently and avoid crowded areas during cold and flu season.
• DON’T crush, chew, or break the tablets open.
• DON’T eat grapefruit or drink grapefruit juice, as it can dangerously change how your body absorbs many targeted cancer pills.
• DON’T take any new over-the-counter medicines or herbal supplements without asking your study doctor first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Citarinostat (ACY-241) is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.